Adial Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable
Adial Pharmaceuticals, Inc. (ADIL) reported Increase (Decrease) in Accounts Payable of $1.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.74M, a 1161.18% increase year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$81.64K, a 128.92% decline year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$113.85K, a 8278.59% decline year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-06-30 was $137.70K, a 1.12% decline year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$183.47K, a 1259.31% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2022 was $15.83K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2021 was -$353.77K, a 156.62% decline from fiscal 2020.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2020 was $624.79K, a 590.13% increase from fiscal 2019.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.66M 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | -$81.64K 10-Q · filed 2026-05-08 | ||||||
| 2025-09-30 | -$113.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $23.85K derived: sum of 2 quarters · filed 2026-08-14 | $306.15K 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $137.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $420.00K 10-Q · filed 2026-08-14 | $420.99K 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | $282.30K 10-Q · filed 2026-05-08 | ||||||
| 2024-09-30 | $1.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $140.65K derived: sum of 2 quarters · filed 2025-11-13 | $214.79K 10-Q · filed 2025-11-13 | $228.55K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $139.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $213.40K 10-Q · filed 2025-08-13 | $227.16K derived: sum of 3 quarters · filed 2025-08-13 | $199.38K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $74.14K 10-Q · filed 2025-05-14 | $87.90K derived: sum of 2 quarters · filed 2025-05-14 | $60.13K derived: sum of 3 quarters · filed 2025-05-14 | -$245.64K derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $13.76K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$14.02K derived: sum of 2 quarters · filed 2024-11-13 | -$319.78K derived: sum of 3 quarters · filed 2024-11-13 | -$183.47K 10-K · filed 2024-04-01 | |||
| 2023-09-30 | -$27.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$333.54K derived: sum of 2 quarters · filed 2024-11-13 | -$197.23K 10-Q · filed 2024-11-13 | -$196.16K derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | -$305.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$169.46K 10-Q · filed 2024-08-13 | -$168.38K derived: sum of 3 quarters · filed 2024-08-13 | -$138.40K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $136.31K 10-Q · filed 2023-05-12 | $137.38K derived: sum of 2 quarters · filed 2024-04-01 | $167.36K derived: sum of 3 quarters · filed 2024-04-01 | $23.06K derived: sum of 4 quarters · filed 2024-04-01 | |||
| 2022-12-31 | $1.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $31.05K derived: sum of 2 quarters · filed 2024-04-01 | -$113.24K derived: sum of 3 quarters · filed 2024-04-01 | $15.83K 10-K · filed 2024-04-01 | $108.35K 10-K · filed 2023-03-30 | ||
| 2022-09-30 | $29.98K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | -$114.32K derived: sum of 2 quarters · filed 2023-11-14 | $14.75K 10-Q · filed 2023-11-14 | -$9.29K 10-Q · filed 2022-11-14 | $125.44K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$144.30K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-10-30 | -$15.23K 10-Q/A · filed 2023-10-30 | $333.76K 10-Q · filed 2022-08-15 | $95.46K derived: sum of 3 quarters · filed 2023-10-30 | -$196.76K derived: sum of 4 quarters · filed 2023-10-30 | ||
| 2022-03-31 | $129.07K 10-Q · filed 2023-05-12 | $239.76K derived: sum of 2 quarters · filed 2023-05-12 | -$52.47K derived: sum of 3 quarters · filed 2023-05-12 | -$212.46K derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | $110.69K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$181.54K derived: sum of 2 quarters · filed 2023-03-30 | -$341.52K derived: sum of 3 quarters · filed 2023-03-30 | -$353.77K 10-K · filed 2023-03-30 | |||
| 2021-09-30 | -$292.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$452.21K derived: sum of 2 quarters · filed 2022-11-14 | -$464.46K 10-Q · filed 2022-11-14 | $103.14K derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | -$159.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$172.24K 10-Q · filed 2022-08-15 | $395.36K derived: sum of 3 quarters · filed 2022-08-15 | $200.39K derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | -$12.25K 10-Q · filed 2022-05-16 | $555.35K derived: sum of 2 quarters · filed 2022-05-16 | $360.38K derived: sum of 3 quarters · filed 2022-05-16 | $606.37K derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $567.60K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $372.62K derived: sum of 2 quarters · filed 2022-03-28 | $618.62K derived: sum of 3 quarters · filed 2022-03-28 | $624.79K 10-K · filed 2022-03-28 | $458.54K 10-K · filed 2021-03-22 | ||
| 2020-09-30 | -$194.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $51.02K derived: sum of 2 quarters · filed 2021-11-15 | $57.20K 10-Q · filed 2021-11-15 | -$237.25K derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $245.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $252.17K 10-Q · filed 2021-08-12 | -$42.27K derived: sum of 3 quarters · filed 2021-08-12 | $266.19K derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | $6.18K 10-Q · filed 2021-05-17 | -$288.27K derived: sum of 2 quarters · filed 2021-05-17 | $20.20K derived: sum of 3 quarters · filed 2021-05-17 | $136.13K derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | -$294.44K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $14.02K derived: sum of 2 quarters · filed 2021-03-22 | $129.95K derived: sum of 3 quarters · filed 2021-03-22 | $90.53K 10-K · filed 2021-03-22 | |||
| 2019-09-30 | $308.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $424.39K derived: sum of 2 quarters · filed 2020-11-13 | $384.98K 10-Q · filed 2020-11-13 | ||||
| 2019-06-30 | $115.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $76.52K 10-Q · filed 2020-08-13 | |||||
| 2019-03-31 | -$39.41K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |